hMSC for COVID-19

Phase-Based Estimates
1
Effectiveness
2
Safety
Providence Medical Foundation, Fullerton, CA
COVID-19+1 More
hMSC - Biological
Eligibility
18+
All Sexes
Eligible conditions
COVID-19

Study Summary

This study is evaluating whether a drug may help treat lung injury.

See full description

Eligible Conditions

  • COVID-19
  • Covid19

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Compared to trials

Study Objectives

This trial is evaluating whether hMSC will improve 1 primary outcome and 1 secondary outcome in patients with COVID-19. Measurement will happen over the course of 14 days post treatment.

14 days post treatment
Survival
9 months
Number of patients with treatment-related adverse events as assessed by CTCAE v4.0

Trial Safety

Safety Estimate

2 of 3
This is better than 68% of similar trials

Compared to trials

Trial Design

2 Treatment Groups

Lactated Ringer's Solution
hMSCs
Placebo group

This trial requires 40 total participants across 2 different treatment groups

This trial involves 2 different treatments. HMSC is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.

hMSCs
Biological
hMSCs will be given via IV administration.
Lactated Ringer's Solution
Biological
Lactated Ringer's Solution will be given via IV administration.

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 9 months
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 9 months for reporting.

Closest Location

Providence Medical Foundation - Fullerton, CA

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 5 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Laboratory-confirmed diagnosis of COVID-19 <= 14 days prior to randomization
Bilateral chest radiograph infiltrates.
PaO2:FiO2 ratio of less than 200.
Absence of other clinical conditions that could present in a similar manner (non-infectious pneumonitis, cardiogenic pulmonary edema)
Absence of moribund state that would indicate imminent demise and poor chance of survival.

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can covid-19 be cured?

Add answer

The incidence of severe disease will be reduced, but not entirely eliminated due to the persistence of some disease. In view of the low level of immunity to this novel coronavirus, patients with mild disease can develop severe disease. A significant proportion of people with mild disease will have severe disease and need intensive care. Therefore, an effective vaccine can be developed against this new virus. Also, given the similarity in disease courses of both MERS and SARS coronavirus infections, an effective coronavirus treatment may also be achievable.

Unverified Answer

What is covid-19?

Add answer

Covid-Related Diseases and Infection will cause the loss of life and livelihood for many infected people and those with close contact. The virus is an infectious disease caused by a virus called Severe acute respiratory syndrome virus (SARS-CoV). The virus has caused worldwide health concerns, especially in East Asia. The virus causes a number of symptoms from mild flu-like symptoms to severe pneumonia which can be fatal for some people. The virus spreads easily as a droplet virus and infects people from contact with an infected person.

Unverified Answer

How many people get covid-19 a year in the United States?

Add answer

The U.S. Centers for Disease Control and Prevention (CDC) is planning to update weekly on the case count and hospitalizations from April 17, 2019 until May 10, 2019. The goal of this website is to help clinicians understand how many people are being affected by the outbreak and help them to make the best decision for each patient. This information is also helpful for patients, their loved ones, and their health care providers.\n

Unverified Answer

What causes covid-19?

Add answer

The virus causes respiratory distress and inflammation in humans. People, especially those who have an underlying health condition, are more severely affected. There is an association between cough syndrome and acute exacerbation of COPD. The virus may have previously been present in a person's respiratory tract. While the virus is highly infectious in humans, it is not transmissible mechanically or from person to person. There is currently no treatment for the virus, although the immune system may prevent people with respiratory infection from developing acute respiratory distress syndrome. The virus has been present in humans for several months before it became symptomatic in Wuhan, China, in January 2020.

Unverified Answer

What are the signs of covid-19?

Add answer

Symptoms most commonly involve weakness, fatigue, loss of appetite, fever, cough, chest pain, headache, lethargy, feeling nauseous, vomiting, diarrhea, loss of appetite, chills, coughing up blood, and loss of taste. In some cases it may present with coughing up blood, chest pain, dizziness, difficulty breathing or fainting. While there are no specific cure for the coronavirus, symptoms can be treated with antihistamines (e.g., omalizumab or levocetirizine), a combination of cold liquids and antihistamines such as fexofenadine or hydroxyzine.

Unverified Answer

What are common treatments for covid-19?

Add answer

There are several common treatments for COVID-19, including supportive care and antiviral medications. There is uncertainty in the literature to determine when people should seek medical attention for symptoms of illness. The National Advisory Committee for Aeronautics recommends “to be evaluated by a health care professional as soon as symptoms occur and not wait for lab test results or to self-diagnose” for people without symptoms. There is also uncertainty around the benefits of staying home from work or school when you feel ill and there may be adverse health effects including transmission to others. As new information breaks out for treatment strategies and clinical guidelines, this page will be updated to reflect these recommendations and to include additional links to the right source.

Unverified Answer

Is hmsc safe for people?

Add answer

This is the first study of self-reported adverse effects using the Hmsc, and the results suggest that the Hmsc is safe for people with MS-E. This is supported by the results of the short follow-up period in which we took no adverse effects reported out of the Hmsc survey.

Unverified Answer

What is the primary cause of covid-19?

Add answer

The main cause of covid-19 is human-to-human transmission between people with respiratory symptoms, who are most likely to be in contact with a infected person (i.e., someone who is contagious to a person who has symptoms of an upper respiratory tract infection) in the early stages of the viral infection that becomes serious (called 'critically ill'). It is possible to accurately and efficiently monitor and treat those with mild symptoms of covid-19 in the community, because there is evidence it does not cause lifelong immunity and because most symptomatic infections will not be fatal. However, current evidence in China suggests there is at least one other cause of severe disease, namely the use of an inappropriate type of medical treatment.

Unverified Answer

What is hmsc?

Add answer

Horseshoe bats represent the smallest mammalian native reservoir for infectious hv/hun viruses. The presence of hmsc-like viroids as the only known hv/hun-encoded ribosomal frame-shifting events in bat genomes supports their importance in the evolutionary history of the hv/hun virome.

Unverified Answer

What are the latest developments in hmsc for therapeutic use?

Add answer

Treatment of patients with COVID-19 should begin with antiviral drug treatment based on the disease type. Asymptomatic treatments should be avoided, and patients should be monitored for potential exacerbation of the disease. COVID-19-related fatalities have been reported in many countries and the number of fatalities is likely to rise. There is no specific treatment for any form of acute respiratory infection. Potential therapies include antimalarial agents such as chloroquine, hydroxychloroquine, and lopinavir-ritonavir; as well as antihistamines such as cetirizine, ebastine, and loratadine.

Unverified Answer

Have there been any new discoveries for treating covid-19?

Add answer

There have been no new treatments developed specifically for the treatment of covid-19, but there will undoubtedly be treatments that have been developed, based on the viral mechanisms that are being studied. Most treatment strategies have been developed for other viral infections such as HIV and influenza, therefore, it should not be surprising that, as new studies are published, treatments are being developed for the virus. There is no approved vaccine to mitigate the effects of covid-19, but there is potential that one can be developed in the future, and would be a significant advantage as part of a first line of defence against the pandemic strain.

Unverified Answer

Is hmsc typically used in combination with any other treatments?

Add answer

In SARS, Hmsc is commonly combined with other treatments such as ritonavir as part of the standard care. Results from a recent paper have important implications for the development of clinical trials of treatments for this disease.

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for COVID-19 by sharing your contact details with the study coordinator.